RudaCure (PDG Yongho Kim), une entreprise spécialisée dans le développement de traitements pour les troubles sensoriels, a annoncé le 21st that it a été sélectionnée pour le Ministère de SMEs and Startups' 'Scale-up TIPS' program, recognized for its analgésique non narcotique development capabilities through canal ionique modulation.
'Scale-up TIPS' is a gouvernement private investissement-led R&D programme de soutien that enables prometteur technology-based SMEs and ventures to boldly pursue high-risk, innovant R&D. When a private operator invests KRW 1 billion or more, the gouvernement provides up to KRW 2 billion for investissement-type R&D and up to KRW 1.2 billion over 3 years for investissement-linked R&D.
Grâce à cela program, RudaCure prévoit de recevoir a total of KRW 1.2 billion in support over the next 3 years to accelerate the commercialization of its analgésique non narcotique RCI002 project.
The compound discovered by RudaCure simultaneously acts on both the canal ionique TRPV1 and MOR (Mu-Opioid Receptor). This is a differentiated analgésique non narcotique approach that overcomes the addiction and tolerance issues of existing MOR-targeting analgésiques narcotiques while addressing the body temperature elevation effets secondaires associated with TRPV1 channel modulation.
RudaCure a déclaré : "Grâce à cela Scale-up TIPS selection, we have established a foundation for accelerating the commercialization of the RCI002 project. We will do our best to lead the next-generation analgésique non narcotique market sur la base de our canal ionique modulation technology."